ARS Pharmaceuticals, Inc. (SPRY) stock
SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.65+0.06 (+1.67%)
Close on Nov 17, 2026Market cap $362.98MP/E –Yield –
ARS Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
ARS Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$196.41M. For fiscal 2025 it was -$170.87M, down 1361.2% from the year before. The highest annual figure on record is $13.55M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$170.87M | -1361.2% |
| FY2024 | Dec 31, 2024 | $13.55M | – |
| FY2023 | Dec 31, 2023 | -$59.27M | – |
| FY2022 | Dec 31, 2022 | -$40.08M | – |
| FY2021 | Dec 31, 2021 | -$17.56M | – |
| FY2020 | Dec 31, 2020 | -$31.20M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$60.93M | – |
| Q1 FY2026 | Mar 31, 2026 | -$44.95M | – |
| Q4 FY2025 | Dec 31, 2025 | -$43.49M | -203.5% |
| Q3 FY2025 | Sep 30, 2025 | -$47.05M | – |
| Q2 FY2025 | Jun 30, 2025 | -$39.59M | – |
| Q1 FY2025 | Mar 31, 2025 | -$40.74M | – |
| Q4 FY2024 | Dec 31, 2024 | $42.00M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.47M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.28M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.71M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.41M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.76M | – |
| Q2 FY2023 | Jun 30, 2023 | -$16.67M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.43M | – |
| Q4 FY2022 | Dec 31, 2022 | -$20.50M | -173.5% |
| Q3 FY2022 | Sep 30, 2022 | -$5.68M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.97M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.93M | – |
| Q4 FY2021 | Dec 31, 2021 | $27.89M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.12M | – |
| Q2 FY2021 | Jun 30, 2021 | -$14.14M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.20M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.10M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.03M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.44M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.63M | – |
See a number that looks wrong?